Generic Oncology Sterile Injectable Market

Global Generic Oncology Sterile Injectable Market Size, Share & Trends Analysis, By Product Type (Chemotherapy, Monoclonal Antibodies, Cytokines, and Peptide Hormones), By Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2025458 | Category : Pharmaceuticals | Delivery Format: /

The global generic oncology sterile injectable market is expected to grow at a significant CAGR during the forecast period (2021-2027).  Generic oncology sterile injectables are biologics that have the same active ingredients as the branded version, however, differ solely in the inactive elements. These sterile oncology injectables are used to treat a wide range of cancers, including breast, prostate, colorectal, melanoma, lung, and bronchus cancers. The injectables are commonly used as they are less expensive than branded medications. 

Further, manufacturers present in the US are concentrating on releasing new products to provide low-cost therapy to patients which are driving the market. Moreover, Owing to the increasing number of product launches in the US, North America is anticipated to hold a dominating position in the global generic oncology sterile injectable market. For instance, in September 2019, Mylan N.V. announced Fulvestrant Injection, a generic version of AstraZeneca's Faslodex Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe for the treatment of advanced breast cancer in the US. Asia-Pacific is expected to be the fastest-growing region in the market owing to increased measures taken by key players to expand the presence of their injectables in this region. 

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered
  • Regions Covered- Globally

Competitive Landscape: Eli Lilly & Co., Mylan N.V., Sandoz International GmbH, and Teva Pharmaceutical Industries Ltd., among others. 

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Generic Oncology Sterile Injectable Market by Segment

By Product Type  

Chemotherapy 

Monoclonal Antibodies

Cytokines

Peptide Hormones

By Disease Indication 

Ovarian Cancer

Breast Cancer

Lung Cancer

Pancreatic Cancer

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Generic Oncology Sterile Injectable Market by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World